(Buloxibutid) - 药物靶点：AT2R_在研适应症：新型冠状病毒感染，特发性肺纤维化，2型糖尿病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

C-21、C21(Emeriti Bio AB)、COMPOUND-21

+ [3]

靶点

AT2R

作用机制

AT2R激动剂(血管紧张素II-2型受体激动剂)

治疗领域

感染呼吸系统疾病其他疾病+ [2]

在研适应症

新型冠状病毒感染特发性肺纤维化2型糖尿病+ [2]

非在研适应症

视网膜色素变性系统性硬皮病

原研机构

Vicore Pharma Holding AB

在研机构

Vicore Pharma AB

Emeriti Bio ABVicore Pharma Holding AB

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、孤儿药 (欧盟)

序列信息

Sequence Code 15939045

关联

13

项与 Buloxibutid 相关的临床试验

NCT05831644 / Completed临床1期

A Randomized, Double-blind, Placebo-controlled, 2-way Cross-over Trial Evaluating the Effect of C21 on Endothelial Dysfunction and Safety in Subjects With Type 2 Diabetes Mellitus

This trial is a single-centre, randomized, double-blind, placebo-controlled, 2-way cross-over phase 1b trial evaluating the pharmacodynamic effect of C21 on endothelial dysfunction and safety in subjects with type 2 diabetes mellitus (T2DM).

开始日期2023-04-25

申办/合作机构

Vicore Pharma AB

NCT05830799 / Completed临床1期

A Single-centre, Open-label, Fixed-sequence Trial to Evaluate the Impact of C21 on the Exposure of CYP1A2, CYP2C9, CYP3A4 and P-gp Substrates in Healthy Volunteers

This is a single-centre, open-label, fixed-sequence trial to evaluate the impact of C21 on the exposure of CYP1A2, CYP2C9, CYP3A4 and P-gp substrates in healthy volunteers.

开始日期2023-03-29

申办/合作机构

Vicore Pharma AB

NCT05576155 / Active, not recruiting早期临床1期IIT

Sex Differences in the Dilatory Response of Compound 21

When blood pressure changes, Angiotensin II is produced and released into the bloodstream. This substance can make blood vessels smaller (i.e., vasoconstriction) by acting through Angiotensin II type I receptors (AT1R) to increase blood pressure. Or it can increase the diameter of vessels (i.e., vasodilation) through Angiotensin II type II receptors (AT2R) to decrease blood pressure. These two receptors normally work in balance to maintain blood pressure. However, excess Angiotensin II released in the bloodstream may reduce the sensitivity of AT2Rs, leading to excessive activation of AT1Rs. This results in increased constriction which plays a major role in diseases such as high blood pressure, hardening of the arteries, and heart failure. In the body, Angiotensin II production is reduced in the presence of estrogen, as seen in pre-menopausal women. Pre-menopausal women have a greater protection against cardiovascular diseases compared to age-matched males, likely due to the protective effects of estrogen. However, the extent that estrogen may impact the sensitivity of Angiotensin II receptors in pre-menopausal is unknown.
In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents), the blood vessels in a dime-sized area of the skin are studied in healthy young women and men. As a compliment to these measurements, blood is drawn from the subjects and circulating factors that may contribute to cardiovascular health are measured.

开始日期2022-10-03

申办/合作机构-

100 项与 Buloxibutid 相关的临床结果

登录后查看更多信息

100 项与 Buloxibutid 相关的转化医学

登录后查看更多信息

100 项与 Buloxibutid 相关的专利（医药）

登录后查看更多信息

228

项与 Buloxibutid 相关的文献（医药）

2024-03-23·Journal of biomolecular structure & dynamics

Computational investigation of the impact of potential AT ₂ R polymorphism on small molecule binding

Article

作者: Jaiswal, Varun ; Sharma, Bhanu ; Shahwan, Moayad ; Khan, Mohd Azhar ; AlAjmi, Mohamed F ; Rehman, Md Tabish ; Hussain, Tahir

For more than a century, the renin-angiotensin system (RAS) has been acknowledged for playing a crucial part in the physiological control of arterial pressure, as well as sodium and fluid balance. It is now generally acknowledged that one of the receptor of RAS system i.e. angiotensin type 2 receptor (AT2R) functions as a repair system during pathophysiologic circumstances and performs a significant protective role. Efforts have been made previously to design suitable agonist and antagonist molecules to potentially modulate AT2R. One of the agonists and antagonists, named C21 and EMA401, has been studied in a number of pathological conditions. Additionally, a wide panel of single nucleotide polymorphisms (SNPs) has been reported for AT2R, which might potentially affect the efficacy of these molecules. Therefore, computational investigations have been carried out to analyze all the SNPs (1151) reported in NCBI to find potential SNPs affecting the active site of AT2R, as this domain is still unexplored. Structures of these polymorphic forms were modeled, and in silico drug interaction studies with C21 and EMA401 were carried out. The two mutants (rs868939201 and rs1042852794) that significantly affect the binding affinity as that of the wild type were subjected to molecular dynamics simulations. Our analysis of native and mutant AT2R and their complexes with C21 and EMA401 indicated that the occurrence of these mutations affects the conformation of the protein and has affected the binding of these ligand molecules. The study's findings will aid in the development of better, more versatile medications in the near future, and also in vitro and in vivo studies might be planned in accordance with recent findings.Communicated by Ramaswamy H. Sarma.

Translational stroke research

Angiotensin II Type 2 Receptor Agonism Alleviates Progressive Post-stroke Cognitive Impairment in Aged Spontaneously Hypertensive Rats

Article

作者: Somanath, Payaningal R ; Kamat, Pradip ; Khan, Mohammad Badruzzaman ; Sayed, Mohammed A ; Fagan, Susan C ; Hess, David C ; Jones, Timothy W ; Ergul, Adviye ; Pillai, Bindu ; Alshammari, Abdulkarim ; Li, Weiguo ; Bosomtwi, Asamoah

Hypertension and aging are leading risk factors for stroke and vascular contributions to cognitive impairment and dementia (VCID). Most animal models fail to capture the complex interplay between these pathophysiological processes. In the current study, we examined the development of cognitive impairment in 18-month-old spontaneously hypertensive rats (SHR) before and following ischemic stroke. Sixty SHRs were housed for 18 months with cognitive assessments every 6 months and post-surgery. MRI scans were performed at baseline and throughout the study. On day 3 post-stroke, rats were randomized to receive either angiotensin II type 2 receptor (AT2R) agonist Compound 21 (C21) or plain water for 8 weeks. SHRs demonstrated a progressive cognitive decline and significant MRI abnormalities before stroke. Perioperative mortality within 72 h of stroke was low. Stroke resulted in significant acute brain swelling, chronic brain atrophy, and sustained sensorimotor and behavioral deficits. There was no evidence of anhedonia at week 8. C21 enhanced sensorimotor recovery and ischemic lesion resolution at week 8. SHRs represent a clinically relevant animal model to study aging and stroke-associated VCID. This study underscores the importance of translational disease modeling and provides evidence that modulation of the AT2R signaling via C21 may be a useful therapeutic option to improve sensorimotor and cognitive outcomes even in aged animals.

2024-02-01·Peptides

Development of an automated, high-throughput assay to detect angiotensin AT2-receptor agonistic compounds by nitric oxide measurements in vitro

Article

作者: Steckelings, U Muscha ; Sumners, Colin ; Stage, Tore Bjerregaard ; Souza-Silva, Igor Maciel ; Nazarova, Antonina L ; Mortensen, Christina ; Katritch, Vsevolod ; Peluso, A Augusto

Angiotensin AT₂-receptor (AT₂R) agonists have shown a wide range of protective effects in many preclinical disease models. However, the availability of AT₂R-agonists is very limited due to the lack of high-throughput assays for AT₂R-agonist identification. Therefore, we aimed to design and validate an assay for high-throughput screening of AT₂R-agonist candidates. The assay is based on nitric oxide (NO) release measurements in primary human aortic endothelial cells (HAEC), in AT₂R-transfected CHO cells (AT₂R-CHO) or in non-transfected CHO cells (Flp-CHO) using the fluorescent probe DAF-FM diacetate. It is run in 96-well plates and fluorescence signals are semi-automatically quantified. The assay was tested for sensitivity (recognition of true positive results), selectivity (recognition of true negative results), and reliability (by calculating the repeatability coefficient (RC)). The high-throughput, semi-automated method was proven suitable, as the NO-releasing agents C21, CGP42112A, angiotensin-(1-7) and acetylcholine significantly increased NO release from HAEC. The assay is sensitive and selective, since the established AT₂R-agonists C21, CGP42112A and angiotensin II significantly increased NO release from AT₂R-CHO cells, while the non-AT₂R-agonists angiotensin-(1-7) and acetylcholine had no effect. Assay reliability was shown by high-throughput screening of a library comprised of 40 potential AT₂R-agonists, of which 39 met our requirements for reliability (RC ≤ 20% different from RC for C21). Our newly developed high-throughput method for detection of AT₂R-agonistic activity was proven to be sensitive, selective, and reliable. This method is suitable for the screening of potential AT₂R-agonists in future drug development programs.

28

项与 Buloxibutid 相关的新闻（医药）

2024-05-31

·BioSpace

Increase of Number of Shares and Votes in Vicore Pharma

STOCKHOLM, SE / ACCESSWIRE / May 31, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 31, 2024 - Vicore Pharma Holding AB (STO: VICO) ("Vicore") announced today that the number of Vicore shares and votes has increased following the exercise of warrants with subsequent delivery of shares to a participant in the incentive program Board LTIP 2023. The shares were issued through the exercise of 11,025 share rights, which are entitled to an equal number of shares. Through the share awards, the number of outstanding shares and votes increased by 11,025 and the share capital by 5,512.499947 SEK. As of today, the total number of registered shares and votes amount to 111,734,004. Furthermore, the registered share capital amounts to 55,867,001.457610 SEK. About Vicore Pharma Holding AB (a clinical-stage biopharmaceutical company) Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) recently completing a phase 2a study in IPF. Almee™ (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, reflecting its potential to have transformative impact. Using its unique expertise in ATRAG chemistry and biology, Vicore is further fueling its pipeline with several new therapies across additional potential indications. The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see This information is information that Vicore Pharma Holding is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-05-31 09:00 CEST. Attachments Increase of number of shares and votes in Vicore Pharma SOURCE: Vicore Pharma Holding View the original press release on accesswire.com

临床2期突破性疗法

2024-05-20

·药明康德

治疗DMD等肌肉疾病的潜在“first-in-class”抗体偶联ASO疗法，改善肺纤维化的小分子疗法……

▎药明康德内容团队编辑Dyne Therapeutics公布抗体偶联反义寡核苷酸疗法积极临床结果Dyne Therapeutics今日公布了分别用于治疗强直性肌营养不良1型（DM1）和杜氏肌营养不良（DMD）的抗体偶联反义寡核苷酸（ASO）疗法DYNE-101和DYNE-251的积极1/2期临床试验结果。该公司表示，这些结果继续支持使用加速批准通道开发这两款ASO疗法。在1/2期临床试验ACHIEVE中，DYNE-101（5.4 mg/kg）在第3个月时表现出剂量依赖性剪接校正，剪接校正比例达到27%。此外，DYNE-101改善患者的肌肉强直、肌肉力量以及多种患者报告的功能性和疲惫指标。在1/2期临床试验DELIVER中，DYNE-251（10 mg/kg）在6个月时将抗肌萎缩蛋白（dystrophin）的表达水平提高到接受标准治疗患者的10倍。多种功能性检测也显示出接受DYNE-251治疗患者的功能改善。Dyne Therapeutics的抗体偶联ASO由靶向肌肉表面表达的转铁蛋白受体1（TfR1）的抗体和ASO偶联生成。这一技术旨在实现靶向肌肉组织的ASO递送。▲抗体偶联ASO平台的示意图（图片来源：Dyne Therapeutics公司官网）改善肺功能并逆转肺纤维化，小分子疗法2期临床结果积极Endeavor BioMedicines公司日前宣布在研疗法ENV-101在治疗特发性肺纤维化（IPF）的2a期临床试验中获得积极结果。12周后，接受ENV-101治疗的IPF患者的肺功能和总肺容量（TLC）获得显著改善，多个量化检测肺纤维化的指标得到逆转。新闻稿指出，这些数据支持ENV-101作为首个改变疾病进程的IPF疗法。试验数据显示，接受ENV-101治疗的患者在试验的12周内肺功能显著改善，预测用力肺活量百分比（ppFVC）从基线提高了1.9%，而安慰剂组患者的ppFVC平均下降了1.3%（P=0.035）。接受ENV-101治疗的患者在12周时TLC平均增加了200 mL，而安慰剂组患者平均下降了56 mL（P=0.005）。在接受ENV-101治疗的患者中，80%患者的TLC增加，而接受安慰剂的患者中有70%患者的TLC下降。ENV-101旨在通过抑制过度激活的Hedgehog（Hh）信号通路来提高患者的肺功能并逆转患者肺部的纤维化。Hh通路是一个伤口愈合信号通路，当其异常活跃时，会导致肺部形成瘢痕组织。现有疗法只能稍微减缓肺功能下降，但并未解决疾病根源，且由于耐受性问题，大多数患者难以长期使用。ENV-101提供了一种新的方法，可能中止甚至逆转纤维化进程。Vicore Pharma小分子疗法显著改善IPF患者肺功能Vicore Pharma日前发布了在研血管紧张素II型受体激动剂buloxibutid治疗初治IPF患者的2a期临床试验的最终数据。该试验在主要和次要终点上均显示出积极结果，表现出卓越的安全性、耐受性和疗效。在36周的治疗期间，buloxibutid改善了基于用力肺活量（FVC）检测的肺功能。未经治疗的患者在36周内FVC大约下降180 mL。在AIR试验中，患者的FVC从基线到第36周平均增加了216 mL，比未经治疗的患者高出近400 mL（n=28，p<0.001）。▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料：[1] Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints. Retrieved May 20, 2024, from https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-announces-new-clinical-data-achieve-trial-dyne[2] New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines’ ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis. Retrieved May 20, 2024, from https://www.businesswire.com/news/home/20240519406386/en/[3] Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis. Retrieved May 20, 2024, from https://vicorepharma.com/mfn_news/vicore-announces-positive-final-results-from-the-phase-2a-air-trial-demonstrating-buloxibutid-improves-lung-function-over-36-weeks-in-patients-with-idiopathic-pulmonary-fibrosis/免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床结果临床2期寡核苷酸加速审批

2024-05-20

·FierceBiotech

Vicore's bet pays off as pulmonary fibrosis drug improves lung function in phase 2

Vicore Pharma CEO Ahmed Mousa hailed today’s results as “exceeding our expectations.” Having stacked all its chips on the idiopathic pulmonary fibrosis (IPF) treatment buloxibutid, Vicore Pharma’s bet may be paying off. The Swedish biotech has unveiled final phase 2a data showing the angiotensin II type 2 receptor agonist improves lung function. Specifically, patients who received the drug saw an average 216-mL increase in their forced vital capacity—a measure of how much air can be exhaled—after 36 weeks. This was nearly 400 mL above the capacity seen across untreated patients, Vicore noted, hitting the trial’s primary endpoint. Buloxibutid was also safe and well tolerated with no drug-related serious adverse events and good gastrointestinal tolerability, said Vicore, which is presenting the findings at the American Thoracic Society International Conference. Patients received a 100-mg dose of the drug orally twice daily. The trial saw investigators evaluate the benefits and risks to patients at both weeks 12 and 24 to determine whether they needed to be switched to standard-of-care. At both checkups, 97% of patients showed positive outcomes and continued with their treatment. Buloxibutid’s clinical impact was also backed up by measurements of two biomarkers. Researchers saw a drop in plasma levels of the profibrotic cytokine TGFβ1, which is known to drive processes involved in IPF. They also noted an increase in levels of collagenase MMP-13, which has the potential to degrade fibrosis. The biotech is now advancing the drug into a phase 2b trial that will assess a change in forced vital capacity at 52 weeks. Vicore CEO Ahmed Mousa hailed today’s results as “exceeding our expectations.” “Taking together the biomarker data and the compelling improvement in FVC over 36 weeks, we believe that buloxibutid has disease-modifying potential,” Mousa added. Vicore went all-in on buloxibutid back in January, discontinuing its preclinical immune-mediated inflammatory diseases program to focus resources on the IPF asset. The following month, Nippon Shinyaku handed over $10 million in upfront cash for the Japanese rights to buloxibutid. The Swedish biotech is also working on a cognitive-behavioral-therapy-based digital therapeutic for the treatment of anxiety in pulmonary fibrosis, dubbed AlmeeTM.

临床2期临床结果

100 项与 Buloxibutid 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床3期	美国	Vicore Pharma AB	2021-09-16
新型冠状病毒感染	临床3期	阿根廷	Vicore Pharma AB	2021-09-16
新型冠状病毒感染	临床3期	巴西	Vicore Pharma AB	2021-09-16
新型冠状病毒感染	临床3期	哥伦比亚	Vicore Pharma AB	2021-09-16
新型冠状病毒感染	临床3期	捷克	Vicore Pharma AB	2021-09-16
新型冠状病毒感染	临床3期	印度	Vicore Pharma AB	2021-09-16
新型冠状病毒感染	临床3期	菲律宾	Vicore Pharma AB	2021-09-16
新型冠状病毒感染	临床3期	俄罗斯	Vicore Pharma AB	2021-09-16
新型冠状病毒感染	临床3期	南非	Vicore Pharma AB	2021-09-16
新型冠状病毒感染	临床3期	乌克兰	Vicore Pharma AB	2021-09-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04533022 (AIR, ATS2024) 人工标引	临床2期	特发性肺纤维化	46	Buloxibutid	鏇淵鏇廠繭窪繭積獵製(鏇憲淵範膚鏇鏇網網餘) = 衊艱積窪鬱糧鬱糧齋糧顧願鑰觸壓衊構艱構獵 (簾廠鏇壓醖窪憲艱願醖, -150~+50) 更多	积极	2024-04-29
NCT04880642 (CTgov)	临床3期	新型冠状病毒感染	272	C21 (C21 Treatment)	範窪醖願襯餘衊艱積鑰(壓蓋壓醖壓餘網壓窪鏇) = 範蓋鏇糧構鬱艱顧簾積觸網製鑰齋獵窪繭願鏇 (壓憲糧鏇艱網夢鏇鬱鹽, 範觸觸構壓範積築願衊 ~ 積構顧淵簾鏇願積齋獵) 更多	-	2023-12-14
				placebo (Placebo Treatment)	範窪醖願襯餘衊艱積鑰(壓蓋壓醖壓餘網壓窪鏇) = 衊鹽憲選構願繭醖餘齋觸網製鑰齋獵窪繭願鏇 (壓憲糧鏇艱網夢鏇鬱鹽, 製繭蓋獵衊憲淵鏇淵構 ~ 糧鹹齋鑰廠醖衊築齋蓋) 更多
NCT04533022 (AIR, Corporate Publications) 人工标引	临床2期	特发性肺纤维化	45	C21	簾鏇繭築顧齋願醖網簾(壓遞鹹齋艱糧壓醖夢窪) = 積夢鹹鹽積淵淵繭繭範觸艱膚願觸範醖網範鹽 (積築憲鑰衊製餘範窪顧 ) 更多	积极	2022-11-05
AIR (ERS2022)	临床2期	特发性肺纤维化	21	C21 100 mg	願選夢襯醖繭網壓簾餘(衊鏇窪鏇鏇顧夢鏇餘艱) = no signals of gastro-intestinal toxicity 襯窪鬱鏇壓構願觸壓繭 (淵觸壓鑰醖鑰遞艱廠簾 ) 更多	积极	2022-09-04
NCT04452435 (ATTRACT, ESC2022)	临床2期	新型冠状病毒感染 NT-proBNP	206	C21	醖餘簾衊積獵憲獵簾襯(積顧鏇憲鬱網衊鏇獵鬱) = 選蓋齋製積蓋襯積醖範構淵衊顧廠鏇選獵獵製 (鹽廠選鹹壓醖壓繭築繭 )	-	2022-08-29
				Placebo	醖餘簾衊積獵憲獵簾襯(積顧鏇憲鬱網衊鏇獵鬱) = 淵齋夢繭襯鏇網艱顧積構淵衊顧廠鏇選獵獵製 (鹽廠選鹹壓醖壓繭築繭 )
NCT04388176 (Pubmed)	临床2期	雷诺病	20	C21 (200mg)	襯鑰齋鏇鏇艱遞選淵鑰(淵窪獵獵積膚蓋觸醖鏇) = 製獵壓繭範願醖餘憲窪積窪願艱積壓糧鏇蓋範 (構艱廠鹽網膚鏇選簾範 ) 更多	积极	2022-07-27
				Placebo	襯鑰齋鏇鏇艱遞選淵鑰(淵窪獵獵積膚蓋觸醖鏇) = 繭膚觸糧艱鹹觸築醖簾積窪願艱積壓糧鏇蓋範 (構艱廠鹽網膚鏇選簾範 ) 更多
NCT04452435 (ATTRACT, Pubmed) 人工标引	临床2期	新型冠状病毒感染	106	C21	鏇齋壓構糧積糧遞選夢(齋繭鬱膚糧鏇糧窪遞艱) = 獵願醖構齋襯夢遞壓壓積襯觸鏇鬱淵鏇選積觸 (夢顧鏇襯顧積願襯網醖 )	积极	2021-11-01
				Placebo	鏇齋壓構糧積糧遞選夢(齋繭鬱膚糧鏇糧窪遞艱) = 簾選蓋顧鬱齋淵鏇鏇淵積襯觸鏇鬱淵鏇選積觸 (夢顧鏇襯顧積願襯網醖 )
NCT04452435 (ATTRACT, PRNewswire) 人工标引	临床2期	新型冠状病毒感染	106	C21	鹽廠鹽鏇壓鏇艱願淵憲(醖鏇鹽衊鏇齋願鏇膚獵) = Although the primary endpoint (reduction in CRP) was not different between C21 and placebo treated patients after seven days of treatment, 窪窪窪願鹽襯網鹽淵鑰 (糧觸積鏇膚夢顧齋積鹽 ) 更多	积极	2021-10-25
				Placebo
ISC2015	N/A	再灌注损伤	16	Compound 21	艱積獵壓獵鹹繭醖鹽鹽(鏇遞鹹積獵網鏇鬱廠觸) = 鹹糧獵範願範選膚膚製構構鬱膚壓餘遞鬱淵淵 (膚製選鹽觸憲繭積糧窪 )	-	2015-02-01
				Saline	艱積獵壓獵鹹繭醖鹽鹽(鏇遞鹹積獵網鏇鬱廠觸) = 窪選範衊願餘範繭壓鹹構構鬱膚壓餘遞鬱淵淵 (膚製選鹽觸憲繭積糧窪 )